$HEPA News

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Hepion Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

Hepion Pharmaceuticals shares are trading higher after the company announced it signed a binding letter of intent with New Day Diagnostics to license diagnostic tests for celiac disease.

Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics LLC To In-License Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And HCC

Hepion Pharmaceuticals Announces Reverse Stock Split

Hepion Pharmaceuticals shares are trading lower after the company announced a 1-for-50 reverse stock split.

Hepion Pharmaceuticals Announces 1-For-50 Reverse Stock Split Effective March 17, 2025

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

Hepion Pharmaceuticals shares are trading lower after the company announced a $9 million public offering.

Hepion Pharmaceuticals Announces $9M Public Offering

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Hepion Pharmaceuticals shares are trading lower. The company announced the termination of a merger agreement with Pharma Two B.

Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B Ltd.; Neither Party Will Be Required To Pay The Other A Termination Fee As A Result Of The Mutual Decision To Terminate The Agreement

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Hepion Pharmaceuticals Sent An Open Letter To Shareholders Urging Them To Vote For Hepion's Proposed Merger With Pharma Two B At The Company's Upcoming Special Meeting Of Stockholders On December 12

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

Hepion Pharmaceuticals shares are trading higher after announcing SEC approval for its merger with Pharma Two B. The deal is expected to close in Q4 2024 pending shareholder and regulatory approvals.